This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 - Aging Research provides funding of $766,269 to support the development of ALTENEX, an exosome-based biologic drug for treating tendinopathy, a degenerative age-related tendon disorder. The recipient organization, New York R&D Center For Translational Medicine And Therapeutics, Inc., will conduct preclinical studies to evaluate the efficacy, safety, and pharmacokinetics of ALTENEX in animal models of tendinopathy. The research aims to advance this novel stem cell-derived therapeutic intervention toward clinical trials and potential FDA approval as a disease-modifying treatment for this age-associated medical condition.
Generated 3/18/25, 5:11 AM